MALDI-TOF-MS for rapid screening analysis of M-protein in serum

Jie Li; Anping Xu; Weijie Xie; Bowen Li; Cunliang Yan; Yong Xia; Chao Liang; Ling Ji

doi:10.3389/fonc.2022.1073479

MALDI-TOF-MS for rapid screening analysis of M-protein in serum

Jie Li^*
, Anping Xu
, Weijie Xie
, Bowen Li
, Cunliang Yan
, Yong Xia
, Chao Liang^*
, Ling Ji^*

^*Corresponding author for this work

Chinese Medicine - Teaching and Research Division

Research output: Contribution to journal › Journal article › peer-review

11 Citations (Scopus)

Abstract

Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.

Original language	English
Article number	1073479
Number of pages	8
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.1073479
Publication status	Published - 15 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

User-Defined Keywords

M-protein
MALDI-TOF-MS
plasma cell dyscrasias
screening test
serum

Access to Document

10.3389/fonc.2022.1073479Licence: CC BY

Cite this

@article{3e322efb352c45d1b6cc0bb984348863,

title = "MALDI-TOF-MS for rapid screening analysis of M-protein in serum",

abstract = "Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.",

keywords = "M-protein, MALDI-TOF-MS, plasma cell dyscrasias, screening test, serum",

author = "Jie Li and Anping Xu and Weijie Xie and Bowen Li and Cunliang Yan and Yong Xia and Chao Liang and Ling Ji",

note = "This work was supported by the National Natural Science Foundation of China (No. 82104216), Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515011450), Shenzhen Project of Science and Technology (No. JCYJ20190809094007719, No. JCYJ20190809095203586), and the fund of “San-ming” Project of Medicine in Shenzhen, China (No. SZSM201812088). Publisher Copyright: Copyright {\textcopyright} 2022 Li, Xu, Xie, Li, Yan, Xia, Liang and Ji.",

year = "2022",

month = dec,

day = "15",

doi = "10.3389/fonc.2022.1073479",

language = "English",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - MALDI-TOF-MS for rapid screening analysis of M-protein in serum

AU - Li, Jie

AU - Xu, Anping

AU - Xie, Weijie

AU - Li, Bowen

AU - Yan, Cunliang

AU - Xia, Yong

AU - Liang, Chao

AU - Ji, Ling

N1 - This work was supported by the National Natural Science Foundation of China (No. 82104216), Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515011450), Shenzhen Project of Science and Technology (No. JCYJ20190809094007719, No. JCYJ20190809095203586), and the fund of “San-ming” Project of Medicine in Shenzhen, China (No. SZSM201812088). Publisher Copyright: Copyright © 2022 Li, Xu, Xie, Li, Yan, Xia, Liang and Ji.

PY - 2022/12/15

Y1 - 2022/12/15

N2 - Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.

AB - Monoclonal immunoglobin (M-protein) is a serum biomarker for the diagnosis of plasma cell dyscrasias. Despite limitation of analytical sensitivity and resolution, serum protein electrophoresis and immunofixation electrophoresis are still the front-line tests for the detection of M-proteins. Herein, we developed a MALDI-TOF Mass spectrometry-based method for the screening test of M-proteins in human serum. Based on the unique mass signature of different immunoglobin isotypes, M-Proteins could be rapidly identified and typed. The method demonstrated with high analytical performance and throughput, rapid and simple, which could be a new choice for the diagnosis of plasma cell dyscrasias.

KW - M-protein

KW - MALDI-TOF-MS

KW - plasma cell dyscrasias

KW - screening test

KW - serum

UR - https://www.scopus.com/pages/publications/85145082026

UR - https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1073479/full

U2 - 10.3389/fonc.2022.1073479

DO - 10.3389/fonc.2022.1073479

M3 - Journal article

AN - SCOPUS:85145082026

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1073479

ER -

MALDI-TOF-MS for rapid screening analysis of M-protein in serum

Abstract

UN SDGs

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this